trans-(4-methylaminomethyl-cyclohexyl)-methanol | 1378849-38-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: trans-(4-methylaminomethyl-cyclohexyl)-methanol
• 英文别名: [4-(methylaminomethyl)cyclohexyl]methanol
• CAS: 1378849-38-7
• 化学式: C₉H₁₉NO
• 分子量: 157.256
• InChiKey: UJARIIGRDCMOQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯甲氧羰酰琥珀酰亚胺 、 trans-(4-methylaminomethyl-cyclohexyl)-methanol 以 甲醇 为溶剂， 生成 trans-(4-hydroxymethyl-cyclohexylmethyl)-methyl-carbamic acid benzyl ester
  参考文献：
  名称：

  Substituted cyclohexane derivatives

  摘要：

  本发明提供了以下式(I)1的化合物，其中A1、A2、A3、A4、A5、A6、A7、A8、A9、A10、U、V、W、m、n和p如规范中所示，并其药学上可接受的盐。这些化合物可用于治疗和/或预防与2,3-氧化甾二烯-鲑鲈固醇环化酶相关的疾病，如高胆固醇血症和高脂血症。

  公开号：

  US20030199550A1
• 作为产物：
  描述：

  tert-butyl N-[[4(hydroxymethyl)cyclohexyl]methyl]carbamate 以 四氢呋喃 为溶剂， 生成 trans-(4-methylaminomethyl-cyclohexyl)-methanol
  参考文献：
  名称：

  Substituted cyclohexane derivatives

  摘要：

  本发明提供了以下式(I)1的化合物，其中A1、A2、A3、A4、A5、A6、A7、A8、A9、A10、U、V、W、m、n和p如规范中所示，并其药学上可接受的盐。这些化合物可用于治疗和/或预防与2,3-氧化甾二烯-鲑鲈固醇环化酶相关的疾病，如高胆固醇血症和高脂血症。

  公开号：

  US20030199550A1

文献信息

• Hydroxyalkylamide derivatives
  申请人：Ackermann Jean

  公开号：US20050009906A1

  公开（公告）日：2005-01-13

  The present invention relates to compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X, W, m and n are as defined hereinabove. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualane-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

  本发明涉及以下式（I）的化合物 其中R 1 ，R 2 ，R 3 ，R 4 ，X，W，m和n如上所定义。这些化合物可用于治疗和/或预防与2,3-氧化齐墩果烷-鲁米叶酯环化酶相关的疾病，如高胆固醇血症、高脂血症、动脉硬化、血管疾病、真菌病、寄生虫感染、胆结石、肿瘤和/或过度增生性疾病，以及治疗和/或预防糖耐量受损和糖尿病。
• Aminoalkylamide substituted cyclohexyl derivatives
  申请人：Ackermann Jean

  公开号：US20050065210A1

  公开（公告）日：2005-03-24

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , U, V, W, k and m are as defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasit infections, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

  本发明涉及式I的化合物 其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，U，V，W，k和m如描述和权利要求中所定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物可用于治疗和/或预防与2,3-氧化齐墩果烷-鲍壳甾醇环化酶相关的疾病，如高胆固醇血症、高脂血症、动脉硬化、血管疾病、真菌病、寄生虫感染、胆结石、肿瘤和/或过度增殖性疾病，以及治疗和/或预防糖耐量受损和糖尿病。
• [EN] BROAD-SPECTRUM CARBAPENEMS<br/>[FR] CARBAPÉNÈMES À LARGE SPECTRE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2021101620A1

  公开（公告）日：2021-05-27

  The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.

  本公开提供了广谱头孢菌素衍生物和制药组合物，用于治疗细菌感染，并提供了使用这些衍生物和/或组合物治疗此类感染的方法。
• MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Tran Thuy-Anh

  公开号：US20110053958A1

  公开（公告）日：2011-03-03

  The present invention relates to amide derivatives of Formula (XIIIa) and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH); idiopathic PAH; familial PAH; PAH associated with a collagen vascular disease, a congenital heart disease, portal hypertension, HIV infection, ingestion of a drug or toxin, hereditary hemorrhagic telangiectasia, splenectomy, pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH); PAH with significant venous or capillary involvement; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  本发明涉及式（XIIIa）的酰胺衍生物及其药物组合物，其调节PGI2受体的活性。本发明的化合物和药物组合物针对以下治疗方法有用：肺动脉高压（PAH）；特发性PAH；家族性PAH；与胶原血管病、先天性心脏病、门静脉高压、HIV感染、药物或毒素摄入、遗传性出血性毛细血管扩张症、脾切除、肺静脉闭塞病（PVOD）或肺毛细血管瘤病（PCH）相关的PAH；有显著静脉或毛细血管参与的PAH；血小板聚集；冠状动脉疾病；心肌梗死；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血栓形成在冠状动脉成形术或冠状动脉搭桥手术个体中或在患有心房颤动的个体中；动脉粥样硬化；动脉粥样硬化性血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病性周围神经病、糖尿病性肾病或糖尿病性视网膜病变；青光眼或其他眼部异常内压疾病；高血压；炎症；银屑病；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Ethylene alpha-olefin mannich base viscosity index improver/dispersant additives
  申请人：EXXON CHEMICAL PATENTS INC.

  公开号：EP0357215A1

  公开（公告）日：1990-03-07

  The present invention is directed to oil-soluble lubricating oil viscosity index improver/dispersant additives comprising Mannich Base condensates of a grafted ethylene copolymer, an optionally alkyl-substituted N-hydroxyaryl compound, an aldehdye, and a monosecondary amine, whereby oil solutions, particularly oil concentrates, of said additives which are characterized by minimal viscosity change over an extended period of time. These additives comprise a copolymer of ethylene with one or more C3 to C28 alpha-olefins, preferably propylene, which have been grafted with acid moieties, e.g. maleic anhydride, preferably using a free radical initiator in a solvent such as a lubricating oil, which is then either (a) reacted with an N-hydroxyaryl amine and then condensed with an aldehyde and a monosecondary amine to form the Mannich Base viscosity index improver/dispersant material, or (b) reacted with a preformed Mannich Base condensate of an N-hydroxyaryl amine. aldehyde and the monosecondary amine. The invention also relates to process for preparing the preceding products and their use in oil compositions.

  本发明涉及油溶性润滑油粘度指数改进剂/分散剂添加剂，该添加剂由接枝乙烯共聚物、任选烷基取代的 N-羟基芳基化合物、醛染料和单仲胺的曼尼希碱缩合物组成。这些添加剂包括乙烯与一种或多种 C3 至 C28 α-烯烃（最好是丙烯）的共聚物，该共聚物已与酸接枝，例如马来酸酐，最好在润滑油等溶剂中使用自由基引发剂，然后(a) 与 N-羟基芳基胺反应，再与醛和单仲胺缩合，形成曼尼希碱粘度指数改进剂/分散剂材料，或 (b) 与 N-羟基芳基胺、醛和单仲胺的预制曼尼希碱缩合物反应。本发明还涉及上述产品的制备工艺及其在油类组合物中的用途。